Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.5 USD | +0.73% | +3.00% | +28.50% |
Apr. 24 | Transcript : Lantern Pharma Inc. - Special Call | |
Apr. 22 | Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 59.08M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -28M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.7
x | P/E ratio 2025 * |
-2.92
x | Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.94% |
Latest transcript on Lantern Pharma Inc.
1 day | +0.73% | ||
1 week | +3.00% | ||
Current month | -37.50% | ||
1 month | -45.16% | ||
3 months | +28.21% | ||
6 months | +99.28% | ||
Current year | +28.50% |
Managers | Title | Age | Since |
---|---|---|---|
Panna Sharma
CEO | Chief Executive Officer | 53 | 18-06-30 |
David Margrave
DFI | Director of Finance/CFO | 64 | 18-05-31 |
Reggie Ewesuedo
CTO | Chief Tech/Sci/R&D Officer | - | 23-03-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Panna Sharma
CEO | Chief Executive Officer | 53 | 18-06-30 |
Director/Board Member | 73 | 22-06-07 | |
Donald Keyser
CHM | Chairman | 71 | 17-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 5.5 | +0.73% | 128,985 |
24-04-25 | 5.46 | +1.49% | 124,629 |
24-04-24 | 5.38 | -6.76% | 97,934 |
24-04-23 | 5.77 | +0.87% | 127,436 |
24-04-22 | 5.72 | +7.12% | 255,410 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.50% | 59.08M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- LTRN Stock